Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

128 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
NF-kappa B as a target for cancer therapy.
Melisi D, Chiao PJ. Melisi D, et al. Expert Opin Ther Targets. 2007 Feb;11(2):133-44. doi: 10.1517/14728222.11.2.133. Expert Opin Ther Targets. 2007. PMID: 17227230 Review.
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial.
Merz V, Zecchetto C, Simionato F, Cavaliere A, Casalino S, Pavarana M, Giacopuzzi S, Bencivenga M, Tomezzoli A, Santoro R, Fedele V, Contarelli S, Rossi I, Giacomazzi S, Pasquato M, Piazzola C, Milleri S, de Manzoni G, Melisi D. Merz V, et al. Among authors: melisi d. Ther Adv Med Oncol. 2020 Jul 7;12:1758835920937889. doi: 10.1177/1758835920937889. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32684989 Free PMC article.
Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer.
Gueorguieva I, Tabernero J, Melisi D, Macarulla T, Merz V, Waterhouse TH, Miles C, Lahn MM, Cleverly A, Benhadji KA. Gueorguieva I, et al. Among authors: melisi d. Cancer Chemother Pharmacol. 2019 Nov;84(5):1003-1015. doi: 10.1007/s00280-019-03931-1. Epub 2019 Sep 3. Cancer Chemother Pharmacol. 2019. PMID: 31482224
First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study.
Taieb J, Prager GW, Melisi D, Westphalen CB, D'Esquermes N, Ferreras A, Carrato A, Macarulla T. Taieb J, et al. Among authors: melisi d, d esquermes n. ESMO Open. 2020 Jan;5(1):e000587. doi: 10.1136/esmoopen-2019-000587. ESMO Open. 2020. PMID: 31958291 Free PMC article. Review.
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.
Merz V, Zecchetto C, Santoro R, Simionato F, Sabbadini F, Mangiameli D, Piro G, Cavaliere A, Deiana M, Valenti MT, Bazan D, Fedele V, Lonardi S, Melisi D. Merz V, et al. Among authors: melisi d. Clin Cancer Res. 2020 Sep 1;26(17):4661-4669. doi: 10.1158/1078-0432.CCR-20-0395. Epub 2020 Jun 12. Clin Cancer Res. 2020. PMID: 32532788 Clinical Trial.
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo.
Lupo F, Piro G, Torroni L, Delfino P, Trovato R, Rusev B, Fiore A, Filippini D, De Sanctis F, Manfredi M, Marengo E, Lawlor RT, Martini M, Tortora G, Ugel S, Corbo V, Melisi D, Carbone C. Lupo F, et al. Among authors: melisi d. Front Cell Dev Biol. 2020 Apr 28;8:308. doi: 10.3389/fcell.2020.00308. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32411709 Free PMC article.
Angiogenesis: a target for cancer therapy.
Tortora G, Melisi D, Ciardiello F. Tortora G, et al. Among authors: melisi d. Curr Pharm Des. 2004;10(1):11-26. doi: 10.2174/1381612043453595. Curr Pharm Des. 2004. PMID: 14754402 Review.
128 results